Chronic kidney disease (CKD) is a long-term condition in which kidney function declines over time, reducing the kidneys’ ability to filter blood and maintain fluid and electrolyte balance.
Unicycive Therapeutics received an FDA Complete Response Letter for its oxylanthanum carbonate NDA resubmission due to third-party manufacturing deficiencies. The FDA raised no efficacy or safety concerns and requested no new data. Labeling discussions are ongoing.
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
Alnylam reported full-year 2025 profitability and $2.987 billion in global net product revenues, driven by U.S. approval and growth of AMVUTTRA. The company also outlined 2026 pipeline goals and additional HELIOS-B analyses for vutrisiran.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Crohn’s disease is linked to kidney stones, dehydration and rare serious kidney complications. Monitoring, hydration and attention to medication-related risks can help protect kidney health.
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm for its longevity platform, expanding from inflammation tracking to specific risk detection. The technology will be integrated into the company's OneTest for Longevity program, with potential applications for improving outcomes in regenerative treatments. The agreement includes revenue sharing and could lead to exclusive commercialization rights for ROKIT in East Asian markets.
A February 2026 review analyzes strategies for kidney-targeted drug delivery systems, examining renal targeting mechanisms and nanocarrier platforms. The review highlights how functionalized nanoparticles can achieve enhanced renal specificity while addressing remaining translational challenges in the field.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07615985 |
A Study to Test the Safety and Blood Levels of PMG1016 in Healthy Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07614659 |
Uppsala Self-Screening of Cardiovascular Health (U-SCREEN) |
RECRUITING | NA |
| NCT07613593 |
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease |
NOT_YET_RECRUITING | |
| NCT07605390 |
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM) |
NOT_YET_RECRUITING | NA |
| NCT07604922 |
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease |
NOT_YET_RECRUITING | NA |
| NCT07597005 |
Red Propolis Supplementation as a Strategy in Chronic Kidney Disease |
RECRUITING | NA |
| NCT07593352 |
Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD) |
RECRUITING | |
| NCT07592000 |
Breakthrough - T1DM and Chronic Kidney Disease |
RECRUITING | PHASE1/PHASE2 |
| NCT07587918 |
Sweet & Sour: Dietary Acid Load in Type 2 Diabetes and Kidney Disease Across Sex and Ethnic Groups |
NOT_YET_RECRUITING | NA |
| NCT07577817 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults. |
NOT_YET_RECRUITING | EARLY_PHASE1 |
